This study is exploring a new treatment for liver cancer that has spread, using three medicines: celecoxib, durvalumab, and tremelimumab. Celecoxib is a pain reliever that may stop cancer cells from growing. Durvalumab and tremelimumab help the body's immune system fight cancer. This study tests how well these drugs work together to treat liver cancer.
Key Points:
- Study Duration: Every 28 days, with each cycle repeating unless disease worsens or side effects are too strong. Follow-ups last up to 2 years.
- Tests Needed: Blood tests, CT or MRI scans, and possibly a tissue biopsy may be required.
- Eligibility: Must be 18+, have a certain health status, and not have certain health conditions or be on conflicting medications.
After treatment, patients are monitored for side effects and the treatment's effectiveness. Participation requires visits for tests and treatments, and agreement to the study's rules. The study aims to see if this combination is safe and works better than existing treatments.
How understandable was the trial content above?
Hard to understand
Easy to understand